<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1529-8019</journal-id><journal-id journal-id-type="publisher-id">DTH</journal-id><journal-title-group><journal-title>Dermatologic Therapy</journal-title></journal-title-group><issn pub-type="ppub">1396-0296</issn><issn pub-type="epub">1529-8019</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7362033</article-id><article-id pub-id-type="doi">10.1111/dth.13986</article-id><article-id pub-id-type="publisher-id">DTH13986</article-id><article-id pub-id-type="other">DTH-20-1155.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Cutaneous manifestations and considerations in <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19 pandemic: A systematic review</article-title><alt-title alt-title-type="left-running-head">Seirafianpour et al.</alt-title></title-group><contrib-group><contrib id="dth13986-cr-0001" contrib-type="author"><name><surname>Seirafianpour</surname><given-names>Farnoosh</given-names></name><xref ref-type="aff" rid="dth13986-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dth13986-cr-0002" contrib-type="author"><name><surname>Sodagar</surname><given-names>Sogand</given-names></name><xref ref-type="aff" rid="dth13986-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dth13986-cr-0003" contrib-type="author"><name><surname>Mohammad</surname><given-names>Arash Pour</given-names></name><xref ref-type="aff" rid="dth13986-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dth13986-cr-0004" contrib-type="author"><name><surname>Panahi</surname><given-names>Parsa</given-names></name><xref ref-type="aff" rid="dth13986-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dth13986-cr-0005" contrib-type="author"><name><surname>Mozafarpoor</surname><given-names>Samaneh</given-names></name><xref ref-type="aff" rid="dth13986-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dth13986-cr-0006" contrib-type="author"><name><surname>Almasi</surname><given-names>Simin</given-names></name><xref ref-type="aff" rid="dth13986-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dth13986-cr-0007" contrib-type="author" corresp="yes"><name><surname>Goodarzi</surname><given-names>Azadeh</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1249-4429</contrib-id><xref ref-type="aff" rid="dth13986-aff-0004">
<sup>4</sup>
</xref><address><email>goodarzi.a@iums.ac.ir</email><email>azadeh_goodarzi1984@yahoo.com</email></address></contrib></contrib-group><aff id="dth13986-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Student Research committee, school of medicine</named-content>
<institution>Iran University of Medical Sciencess</institution>
<city>Tehran</city>
<country country="IR">Iran</country>
</aff><aff id="dth13986-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Dermatologist, Skin Disease and Leishmaniasis Research Center, Department of Dermatology</named-content>
<institution>Isfahan University of Medical Sciences</institution>
<city>Isfahan</city>
<country country="IR">Iran</country>
</aff><aff id="dth13986-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Rheumatology</named-content>
<institution>Rheumatology Research Center, Firoozgar Hospital, Iran University of Medical Sciences (IUMS)</institution>
<city>Tehran</city>
<country country="IR">Iran</country>
</aff><aff id="dth13986-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Rasoul Akram Hospital, Iran University of Medical Sciences (IUMS)</institution>
<city>Tehran</city>
<country country="IR">Iran</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Dr. Azadeh Goodarzi, MD, Assistant Professor, Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran, Mob: 00989123882448 Email: <email>goodarzi.a@iums.ac.ir</email>, <email>azadeh_goodarzi1984@yahoo.com</email>, Postal code: 1445613131 Phone number: 02166514001, Address: Nyayesh Street, Sattarkhan Avenue, Rasoul Akram Hospital, Tehran, Iran<break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>7</month><year>2020</year></pub-date><elocation-id>10.1111/dth.13986</elocation-id><history><date date-type="received"><day>14</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>01</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>06</day><month>7</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> This article is protected by copyright. All rights reserved. <copyright-statement>--><copyright-statement content-type="article-copyright">This article is protected by copyright. All rights reserved.</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DTH-9999-na.pdf"/><abstract><title>Abstract</title><sec id="dth13986-sec-0001"><title>Background</title><p>COVID&#x02010;19 had a great impact on medical approaches among dermatologist</p></sec><sec id="dth13986-sec-0002"><title>Objective</title><p>This systematic review focuses on all skin problems related to COVID&#x02010;19, including primary and secondary COVID&#x02010;related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues</p></sec><sec id="dth13986-sec-0003"><title>Method</title><p>Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May/03/2020. 377 articles assigned to the inclusion and exclusion groups</p></sec><sec id="dth13986-sec-0004"><title>Result</title><p>Eighty&#x02010;nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID&#x02010;19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as &#x0201c;COVID toes&#x0201d; (pernio&#x02010;like acral lesions or vasculopathic rashes). Conclusion: During pandemic, Non&#x02010;infected non&#x02010;at risk patients with immune&#x02010;medicated dermatologic disorders under treatment with immunosuppressive immunomodulators are not needed to alter their regimen or discontinue the therapies. At&#x02010;risk and infection&#x02010;suspected patients needed to dose reduction, interval increase or temporary drug discontinuation (at least 2&#x02009;weeks). Patients with an active COVID&#x02010;19 infection should hold the biologic or non&#x02010;biologic immunosuppressives until the complete recovery occur (at least 4&#x02009;weeks).</p><p>This article is protected by copyright. All rights reserved.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dth13986-kwd-0001">COVID&#x02010;19</kwd><kwd id="dth13986-kwd-0002">corona virus</kwd><kwd id="dth13986-kwd-0003">novel human coronavirus (SARS&#x02010;CoV&#x02010;2)</kwd><kwd id="dth13986-kwd-0004">cutaneous</kwd><kwd id="dth13986-kwd-0005">cutaneous manifestation</kwd><kwd id="dth13986-kwd-0006">skin</kwd><kwd id="dth13986-kwd-0007">skin manifestation</kwd><kwd id="dth13986-kwd-0008">immunomodulator</kwd><kwd id="dth13986-kwd-0009">biologic</kwd><kwd id="dth13986-kwd-0010">immunosupressive</kwd><kwd id="dth13986-kwd-0011">systemic treatment</kwd><kwd id="dth13986-kwd-0012">systematic review</kwd><kwd id="dth13986-kwd-0013">immunosupressant</kwd><kwd id="dth13986-kwd-0014">dermatology</kwd><kwd id="dth13986-kwd-0015">pandemic considerations</kwd><kwd id="dth13986-kwd-0016">recommendation</kwd><kwd id="dth13986-kwd-0017">drug reaction</kwd><kwd id="dth13986-kwd-0018">special</kwd><kwd id="dth13986-kwd-0019">specific skin diseases</kwd><kwd id="dth13986-kwd-0020">dermatitis</kwd><kwd id="dth13986-kwd-0021">eczema</kwd><kwd id="dth13986-kwd-0022">pemphigus</kwd><kwd id="dth13986-kwd-0023">immunobullous</kwd><kwd id="dth13986-kwd-0024">skin rheumatologic disorder</kwd><kwd id="dth13986-kwd-0025">collagen vascular disorder</kwd><kwd id="dth13986-kwd-0026">psoriasis</kwd><kwd id="dth13986-kwd-0027">hidradenitis suppurativa</kwd><kwd id="dth13986-kwd-0028">alopecia</kwd><kwd id="dth13986-kwd-0029">papulosquamous</kwd><kwd id="dth13986-kwd-0030">visits</kwd><kwd id="dth13986-kwd-0031">cosmetic procedure</kwd><kwd id="dth13986-kwd-0032">surgical procedure</kwd><kwd id="dth13986-kwd-0033">teledermatology</kwd><kwd id="dth13986-kwd-0034">health care staff</kwd></kwd-group><counts><fig-count count="0"/><table-count count="5"/><page-count count="1"/><word-count count="400"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.5 mode:remove_FC converted:15.07.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="dth13986-ntgp-0001"><fn id="dth13986-note-2001"><p>This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dth.13986.</p></fn></fn-group></notes></front></article>